MicroRNA Expression Analysis: Clinical Advantage of Propranolol Reveals Key MicroRNAs in Myocardial Infarction
2011

MicroRNA Expression Analysis in Myocardial Infarction

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): Zhu Wenliang, Yang Lei, Shan Hongli, Zhang Yong, Zhou Rui, Su Zhe, Du Zhimin

Primary Institution: Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

Hypothesis

Modulation of key microRNAs could benefit ischemic heart conditions.

Conclusion

Propranolol administration reversed the expression of many dysregulated microRNAs in myocardial infarction, suggesting potential therapeutic targets.

Supporting Evidence

  • Propranolol significantly reduced the infarct size in rats with myocardial infarction.
  • 18 out of 31 dysregulated miRNAs in myocardial infarction were reversed by propranolol treatment.
  • miR-1, miR-29b, and miR-98 were identified as key players in myocardial infarction.

Takeaway

This study found that a medicine called propranolol can help fix some important tiny molecules in the heart that get messed up when someone has a heart problem.

Methodology

A long-term myocardial infarction model in rats was used, and microarray technology was applied to analyze miRNA expression changes due to propranolol treatment.

Limitations

The study may include false positive interactions and predictions of miRNA gene targets.

Participant Demographics

Male Wistar rats, 250-300 g.

Statistical Information

P-Value

0.0016

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1371/journal.pone.0014736

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication